In a phase I trial of the MTA-cooperative PRMT5 inhibitor AMG 193, five of 39 patients with advanced MTAP-deleted solid tumors who had scans following initial treatment experienced partial responses. The responses occurred in five tumor types—esophageal, pancreatic, renal cell, gallbladder, and ovarian Sertoli-Leydig cell cancer.

You do not currently have access to this content.